HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase IV clinical trial. Phase IV trials are used to further test
and monitor the safety of a drug approved by the FDA and to see if the drug has any other
indications that can be used to treat different diseases.
Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of
liver cancer. It is also currently being tested in various other cancers. Sorafenib works by
slowing down and/or stopping the development of new cancer cells and new blood vessels. By
slowing down and/or stopping the growth of new blood vessels around a tumor, it is believed
that sorafenib prevents or slows down the growth of tumors.
The researchers of this study would like to study the effects of sorafenib on hepatitis C by
drawing additional research blood samples from people infected with hepatitis C who are
receiving sorafenib treatment for liver cancer. These tests will measure certain proteins in
the blood (HCV-RNA) which may indicate if sorafenib has any effect on the hepatitis C virus.